In the past few decades, biological drugs and small molecule inhibitors targeting
inflammatory cytokines, immune cells, and intracellular kinases have become the standard …

Autoimmune diseases with B cell–directed therapeutics approved by the US Food and Drug
Administration are surprisingly diverse in clinical manifestations and pathophysiology. In this …

Importance The role of mycophenolate mofetil (MMF) in management of immunoglobulin A
nephropathy (IgAN) remains highly controversial. Objective To evaluate the efficacy and …

Pemphigus and pemphigoid are paradigms for understanding the mechanisms of antibody-
mediated autoimmune disease in humans. In pemphigus, IgG4-predominant autoantibodies …

Background By depleting circulating B lymphocytes, rituximab time-dependently suppresses
coronavirus disease 2019 (COVID-19) vaccines' humoral immunogenicity for a prolonged …

Background Immunoglobulin G (IgG) levels are maintained by the IgG-recycling neonatal Fc-
receptor (FcRn). Pemphigus vulgaris and pemphigus foliaceus are debilitating autoimmune …

The prevalence of immune-mediated disorders, including autoimmune conditions and
allergies, is steadily increasing. However, current therapeutic approaches are often non …

B cells have a pivotal function in the pathogenesis of autoimmune diseases, such as
rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus. In autoimmune …

Biologic therapies targeting B-cells are emerging as an effective strategy to treat a variety of
immune-mediated diseases. One of the most studied B-cell-targeted therapies is rituximab …

Background The risk of infectious complications among patients with pemphigus managed
by rituximab is yet to be precisely elucidated. Objectives To evaluate the risk of infections in …